Navigating the Gulf Pharma Market: Growth, Margins & Disruption

Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I've spent over 20 years building and scaling pharmaceutical businesses across some of the most complex markets in the world.

I started in Europe, then Middle East and Africa, later Emerging Markets. Eventually ended up leading commercial transformation across more than 80 countries from Singapore. That role taught me something important: execution discipline is what separates a good strategy from an actual result.

For the past several years, I've been based in the Dubai, running a business across five Gulf markets: UAE, Saudi Arabia, Kuwait, Bahrain, and Oman. Full P&L responsibility, roughly 70 people across commercial, medical, and marketing. When I took over, the business was at $120 million. We grew it to $170 million in four years while improving profitability at the same time.

What makes the Gulf genuinely interesting is the complexity underneath the surface. You have government procurement sitting next to private insurance. Distributor models that differ by country. Price regulation that moves without much warning. Tender cycles that can shift your forecast overnight. It sharpens you quickly.

I've launched brands, managed portfolio rationalisation, redesigned…